Physician profile
Kevin T Marks
NPI 1679585228
$8,173.32
in general payments reported to CMS, 2019-2025
36 companies · $2,279 in 2025
The $2,279 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,561 · 2020: $630 · 2021: $320 · 2022: $823 · 2023: $1,087 · 2024: $1,473 · 2025: $2,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,296 · Consulting Fee: $475 · Education: $68.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,295.50 |
| Consulting Fee | $475.00 |
| Education | $68.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,440.99 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $916.60 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $881.04 | 2019-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $781.85 | 2019-2025 | Trulance, Xifaxan |
| Pfizer INC. | $428.52 | 2021-2025 | |
| Allergan, INC. | $282.59 | 2019-2020 | |
| Braintree Laboratories, INC. | $259.65 | 2019-2022 | |
| Celltrion USA INC. | $225.46 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Romark Laboratories, Lc | $210.68 | 2019-2020 | |
| Novo Nordisk INC | $196.65 | 2021-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $164.67 | 2020-2024 | Dificid |
| Edwards Lifesciences Corporation | $156.25 | 2022 | |
| Olympus America INC. | $137.28 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $102.35 | 2024-2025 | Voquezna |
| Celgene Corporation | $96.38 | 2021-2023 | Zeposia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $86.81 | 2019-2025 | |
| Ardelyx, INC. | $84.95 | 2022-2024 | Ibsrela |
| Lilly USA, LLC | $81.71 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $72.45 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $66.11 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $64.53 | 2024 | Dupixent |
| Gilead Sciences, INC. | $56.33 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $49.06 | 2020-2024 | |
| Redhill Biopharma INC. | $35.47 | 2024 | Talicia |
| Boston Scientific Corporation | $33.63 | 2023-2025 | Watchman Flx, Cre Pro |
| Qol Medical, LLC | $32.38 | 2019-2020 | |
| Medtronic, INC. | $30.41 | 2024 | Interstim |
| Aspire Bariatrics, INC. | $28.86 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $27.84 | 2019-2020 | |
| Biocon Biologics INC | $24.31 | 2025 | Yesintek |
| Genzyme Corporation | $23.82 | 2024 | |
| Apollo Endosurgery US INC | $21.60 | 2019 | |
| Horizon Therapeutics Plc | $21.12 | 2019 | |
| Ethicon US, LLC | $19.47 | 2019 | |
| Ferring Pharmaceuticals INC. | $18.72 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.